Impaired selective renal filtration captured by eGFR_{cysC}/eGFR_{crea} ratio is associated with mortality in a population based cohort of older women

Linnea Malmgren1,2, Fiona E. McGuigan1,3, Anders Christensson1,4 & Kristina E. Akesson1,3

Deranged renal filtration of mid-sized (5–30 kDa) compared to smaller molecules (< 0.9 kDa) results in increased plasma levels of cystatin C (cysC) compared to creatinine resulting in a low eGFR_{cysC}/eGFR_{crea} ratio. A ratio below 0.6 or 0.7 is termed shrunken pore syndrome (SPS), which in patient based studies is associated with mortality. Reference values for eGFR_{cysC}/eGFR_{crea} ratio, the prevalence of SPS and the consequence of low eGFR_{cysC}/eGFR_{crea} ratio in the general, elderly population are unknown. 75-yr old women (n = 849) from the population-based OPRA cohort, followed for 10-years had eGFR calculated with CKD-EPI study equation, and eGFR_{cysC}/eGFR_{crea} ratio calculated. Mortality risk (HR [95% CI]) was estimated. Women with sarcopenia or on glucocorticoids were excluded. Almost 1 in 10 women (9%) had eGFR_{cysC}/eGFR_{crea} ratio < 0.6 at age 75 and this did not increase appreciably with age. Women with ratio < 0.6 had higher 10-yr mortality risk compared with ratios > 0.9 (HRadj 1.6 [95% CI 1.1–2.5]). In elderly women eGFR_{cysC}/eGFR_{crea} ratio < 0.6 is common and associated with increased mortality. Our results confirm patient-based findings, suggesting that identifying individuals with SPS may be clinically relevant to assessing mortality risk in the elderly.

Decreased kidney function results in lower clearance and increased plasma concentration of glomerular filtration rate (GFR) markers, for example cystatin C (cysC) or the commonly used creatinine. In 2015 Grubb et al. described a new syndrome affecting kidney filtration, characterized by a disturbance in the ability to filter larger i.e. 5–30 kDa sized molecules. Termed Shrunken Pore Syndrome (SPS), this results in elevated plasma concentration of middle sized proteins such as cysC (13.3 kDa) compared to smaller molecules < 0.9 kDa, such as creatinine (0.113 kDa) or water (0.018 kDa)\(^1\),\(^2\),\(^3\), resulting in a low eGFR_{cysC}/eGFR_{crea} ratio.

The kidney is a complex organ and no generally accepted 3D-model of the glomerular filtration barrier exists (4). However, two pathophysiological models are currently suggested to explain the affected filtration quality; decreased pore size and, or thickening of the glomerular basement membrane (GBM) (Fig. 1). A thickening of the GBM would lead to an increased diffusion length of cysC, thus affecting the plasma concentration\(^1\),\(^5\). While the syndrome has been associated with mortality, both in individuals with normal kidney function and those with reduced GFR\(^1\),\(^6\)–\(^8\), to date only one study has follow-up above five years\(^4\), hence, the association to long-term mortality is unknown.

Given the limited literature to date\(^3\) there are many questions to be answered. The first of these surrounds diagnosis. Plasma concentrations of creatinine and cysC, and therefore their respective estimations of GFR (eGFR), differ in SPS. Since creatinine levels are affected by age and sex, to enable comparisons between individuals, diagnosis is therefore based on the ratio of eGFR_{cysC} to eGFR_{crea}, as the eGFR study equations take these two factors into account. However, SPS should only be diagnosed in the absence of non-renal factors influencing creatinine and cystatin C e.g. sarcopenia and glucocorticoid treatment\(^1\),\(^3\). As of yet, no absolute cutoff in the ratio of eGFR_{cysC}/eGFR_{crea} has been defined\(^3\). While most studies use a ratio of < 0.6 or 0.7, some suggest that specific

---

1Department of Clinical Sciences, Lund University, Malmö, Sweden. 2Department of Geriatrics, Skåne University Hospital, Malmö, Sweden. 3Department of Orthopaedics, Skåne University Hospital, Malmö, Sweden. 4Department of Nephrology, Skåne University Hospital, Malmö, Sweden. *Email: kristina.akesson@med.lu.se
clinical settings and conditions could warrant alternative cutoffs. For example, age, eGFR study equation and comorbidities are all factors that could affect the eGFRcysC/eGFRcrea ratio.

The second of these questions is prevalence. Reported prevalence of SPS varies from 0.2 to 36%, but these estimates are primarily based on studies in selected patient cohorts, predominantly with heart disease. The ratio of eGFRcysC/eGFRcrea and hence prevalence in the general population is as yet unknown. Although one paper investigated healthy seniors, it is unclear whether the results are generalizable to a wider elderly population (based on the recruitment strategy and additionally because, while underweight participants were excluded this is only an indirect measurement of sarcopenia).

The next of these questions is chronicity. This disruption in glomerular sieving is closely linked to cardiovascular outcomes but it has also been identified in pregnant women and even children, suggesting that altered ratios of eGFRcysC/eGFRcrea may not just affect the elderly or those with cardiovascular comorbidities. It also raises questions about the stability of the deranged filtration. Although the data from pregnant women indicate a disturbed eGFRcysC/eGFRcrea ratio may be reversible, this has not been confirmed at other ages or in other settings.

The present study aimed to address some of these substantial gaps in knowledge through a longitudinal study, investigating 1044 75 year old women who attended three consecutive follow-ups over 10-years and for whom information on sarcopenia and glucocorticoid treatment was available. Our aims were (1) to longitudinally investigate eGFRcysC/eGFRcrea ratio in community dwelling women, suggest reference values for healthy older adults and determine prevalence of SPS and (2) investigate the association between eGFRcysC/eGFRcrea ratio using different cut offs previously described in the literature and mortality over ten years in a population based setting.

Results
The mean eGFRcysC/eGFRcrea ratio (CKD-EPI) of the 849 women included in the analyses at study start (age 75) was 0.86 (ranging 0.33 to 2.22) based on the individual markers eGFRcysC (64.8 mL/min/1.73 m²) and eGFRcrea (75.3 mL/min/1.73 m²). High blood pressure was common, with 40% on treatment, while 6% reported diabetes, 18% CVD and 14% were current smokers (Table 1).

Prevalence of SPS is dependent on the selected threshold of the eGFRcysC/eGFRcrea ratio. Cross sectionally at age 75 (n = 849), a total of 80 women (9%) had an eGFRcysC/eGFRcrea ratio < 0.6, while 165 (19%) had an eGFRcysC/eGFRcrea ratio < 0.7. Five years later at age 80 (n = 569), 25 women (4%) and 134 (24%) had a ratio < 0.6 and < 0.7, respectively. At the last follow-up investigation (age 85, n = 286), 24 women (8%) had an eGFRcysC/eGFRcrea ratio < 0.6, while 70 women (24%) had a ratio < 0.7 (Table 2). Consequently, by the most common definition (an eGFRcysC/eGFRcrea ratio < 0.6), prevalence of SPS in elderly women amounts to one in ten at age 75 using the CKD-EPI study equation.

Comorbidities were compared for categories of eGFRcysC/eGFRcrea ratio (> 0.7, 0.6–0.69 and < 0.6). Women with a ratio < 0.6 or between 0.6–0.69 were more likely to be on high blood pressure medications compared to those > 0.7 at age 75 and 80 (p = 0.043 and p = 0.015, respectively). However, no difference in distribution of cardiovascular disease or diabetes was observed at any time point (data not shown).

The extended follow-up allowed us to longitudinally investigate two consecutive five year time-windows. Longitudinally, just over half of those women (n = 80) with an eGFRcysC/eGFRcrea ratio < 0.6 at age 75 were alive and attended the five year follow-up (42/80) using the CKD-EPI study equation. Of these, the majority (n = 36)
had ratios that had increased to 0.6 or higher. Correspondingly, at age 80, approximately one third (8/25) of women with eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} < 0.6 were alive and attended the next follow-up visit (age 85). Of these, 5 had an increased ratio of > 0.6. Results were similar for women with a ratio 0.6–0.69, were little less than half attending follow-up at age 80 had increased to a ratio > 0.7, and similarly from age 80–85 (data not shown).

The eGFR threshold for diagnosing chronic kidney disease (CKD) was based on the association between reduced function and mortality below a certain point (16). In this instance, to provide reference values for eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio and evidence of a diagnostic threshold for SPS in averagely healthy older women, we investigated a range of ratios and the relationship to 10-year mortality. Using CKD-EPI study equation and data at age 75, the five categories were: eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio ≥ 0.9 (n = 366), 0.8–0.89 (n = 178), 0.7–0.79 (n = 140), 0.6–0.69 (n = 85) and < 0.6 (n = 80)). Figure 2 shows survival between ages 75–85, a period in which a total of 221 women (26%) died. Although a difference in survival between the five categories was not observed (p = 0.078), women with a ratio < 0.6 had the lowest survival over the ten year period. Conversely, only those with an eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio < 0.6 had increased mortality risk and this remained even after adjustment for covariates, including physical activity level (HR\textsubscript{adj} 1.6, 95% CI [1.1–2.5]), Table 3. Taking eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio as a continuous variable, mortality risk was reduced by half for every increase in ratio (HR\textsubscript{adj} 0.5, 95% CI [0.2–0.9], p = 0.035).

Using the CAPA/LM-rev study equations, at age 75, 3% had an eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio < 0.6 and 7% a ratio < 0.7 (supplementary table S1), hence a lower SPS prevalence. However, the association to mortality was

### Table 1. Baseline characteristics of the OPRA cohort of women all aged 75 at inclusion (n = 849). *Median with interquartile range. **Cardiovascular disease defined as hypertensive treatment in combination with an anticoagulant or lipid-modifying agent, or treatment with only vasodilators.

| Characteristics | Mean (SD) |
|-----------------|-----------|
| Age (years)     | 75.2 (0.14) |
| Body Mass Index (kg/m²) | 26.3 (4.0) |
| Weight (kg)     | 67.9 (10.9) |
| Height (cm)     | 161 (6) |
| p-cysC (mg/L)   | 1.1 (0.3) |
| p-crea (µmol/L) | 68.7 (13.5) |
| eGFR\textsubscript{cysC} (mL/min/1.73 m²) | 64.8 (17.1) |
| eGFR\textsubscript{crea} (mL/min/1.73 m²) | 75.3 (12.5) |
| eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio | 0.86 (0.19) |
| p-CRP* (mg/L)   | 1.8 (2.7) |
| p-calcium (mmol/L) | 2.4 (0.1) |
| p-albumin (g/L) | 40.9 (2.4) |
| p-phosphate (nmol/L) | 1.1 (0.2) |
| s-PTH* (pmol/L) | 4.2 (2.2) |
| s-25(OH)D3 (nmol/L) | 62.5 (19.2) |
| p-TSH* (g/L)    | 1.7 1.6 |
| p-homocysteine* (µmol/L) | 13.9 5.4 |
| s-folate (nmol/L) | 21.1 10.8 |
| p-cobalamin* (nmol/L) | 308 171 |

| n (%): Treatment for high blood pressure 321 (40) |
| Cardiovascular disease** 151 (18) |
| Diabetes 53 (6) |
| Current smoker 116 (14) |

### Table 2. eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio and proportion with shrunken pore syndrome* at ages 75, 80 and 85. Age 75; n = 849, age 80 n = 569, age 85; n = 286. *Defined using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study equation.

| Age | eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio | < 0.6 | 0.6–0.69 | < 0.7 |
|-----|--------------------------------|-------|--------|-------|
| 75  | 80 (9%)                        | 85 (10%) | 165 (19%) |
| 80  | 25 (4%)                        | 109 (19%) | 134 (24%) |
| 85  | 24 (8%)                        | 46 (16%) | 70 (24%) |

Figure 2 shows survival between ages 75–85, a period in which a total of 221 women (26%) died. Although a difference in survival between the five categories was not observed (p = 0.078), women with a ratio < 0.6 had the lowest survival over the ten year period. Conversely, only those with an eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio < 0.6 had increased mortality risk and this remained even after adjustment for covariates, including physical activity level (HR\textsubscript{adj} 1.6, 95% CI [1.1–2.5]), Table 3. Taking eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio as a continuous variable, mortality risk was reduced by half for every increase in ratio (HR\textsubscript{adj} 0.5, 95% CI [0.2–0.9], p = 0.035).

Using the CAPA/LM-rev study equations, at age 75, 3% had an eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio < 0.6 and 7% a ratio < 0.7 (supplementary table S1), hence a lower SPS prevalence. However, the association to mortality was
independent of study equation; using CAPA/LM-rev, women with a ratio < 0.6 had over two times increased mortality risk compared to women with a ratio > 0.9 (HRadj 2.5, 95% CI [1.4–4.5], supplementary table S2). Survival over ten years based on the CAPA/LM-rev study equations is shown in supplementary figure S1.

Discussion

We have investigated eGFRcysC/eGFRcrea ratio in this population based study of elderly women, and found that using the most common disease cutoff, one in ten women could be designated as having shrunken pore syndrome. The eGFRcysC/eGFRcrea ratio < 0.6 was associated with increased mortality risk over ten years.

In patient based cohorts the prevalence of SPS is reportedly between 0.2–11% depending on study equation (CKD-EPI, CAPA or LM-rev) and cutoff level1,7,8,17. In the 75 year old OPRA women, prevalence was 9–19% depending on cutoff. This high prevalence mirrors that in two heart disease populations9,13 and in patients referred for GFR examinations6. It is in stark contrast to a study by Purde et al. in healthy Swiss seniors aged 60 and over (mean age 72), which reported a considerably lower prevalence (< 1%), although study participants may have been healthier than the general senior population4. It should also be noted that a lower eGFRcysC/eGFRcrea ratio (CKD-EPI study equation) was reported in females than in males, a finding confirmed in a recent study linking SPS to female sex11. Given the considerably higher prevalence observed in the single sex, identically aged OPRA cohort it is clear that in terms of better understanding disruptions in the filtration process, age and comorbidities need to be taken into account. Since these two factors have a huge impact on kidney function in general, it is not surprising if this is also the case for diagnosing Shrunken pore syndrome, which may exist with both normal and reduced kidney function6. In addition, the GFR estimating equation is influential; the lower prevalence from CAPA/LM-rev in comparison to CKD-EPI study equations is in line with reports in patients with heart failure13 or undergoing heart surgery7.

At present, no generally accepted pathophysiological explanation for SPS exists, although shrinking of the pore size and thickening of the glomerular basement membrane (GBM) are the main hypotheses1,3. In diabetic glomerulosclerosis, thickening of the GBM may be reversible, at least in its early stages18 and it is possible that this is also the case in SPS, with data from pregnant women suggesting plasma levels of middle sized molecules returned to normal after delivery19. In the present study, there is a suggestion of reversal, since the majority of women with eGFRcysC/eGFRcrea ratio < 0.6 at age 75 had an increased ratio (> 0.6) at age 80. While caution is needed when interpreting the longitudinal data due to low numbers, it could be speculated that creatinine and cystatin C were affected by non-renal factors. Although the present study excluded women with sarcopenia, we

Table 3. Association between eGFRcysC/eGFRcrea ratio at age 75 and 10-year mortality. Model 1 adjusted for: diabetes, treatment for high blood pressure, cardiovascular disease and smoking. Model 2 adjusted for: diabetes, treatment for high blood pressure, cardiovascular disease, smoking and self-reported physical activity (three categories: (1) bedbound or moving with the help of other people, (2) using walking aid, inside and out, (3) walk and exercise unhindered).

| eGFRcysC/eGFRcrea ratio (age 75) | ≥ 0.9 | 0.8–0.89 | 0.7–0.79 | 0.6–0.69 | < 0.6 |
|---|---|---|---|---|---|
| n=366 | n=178 | n=140 | n=85 | n=80 |
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Unadjusted | 1 (ref) | 1.0 (0.7–1.5) | 0.927 | 1.0 (0.7–1.5) | 0.947 | 1.4 (0.9–2.1) | 0.144 | 1.7 (1.1–2.6) | 0.014 |
| Model 1 | 1 (ref) | 1.0 (0.7–1.4) | 0.986 | 1.0 (0.6–1.4) | 0.871 | 1.3 (0.8–2.0) | 0.222 | 1.7 (1.1–2.6) | 0.016 |
| Model 2 | 1 (ref) | 1.0 (0.7–1.5) | 0.897 | 0.9 (0.6–1.4) | 0.702 | 1.1 (0.7–1.8) | 0.545 | 1.6 (1.1–2.5) | 0.022 |

Figure 2. Ten year survival for five categories of eGFRcysC/eGFRcrea ratio. P-value calculated using the log Rank test.
cannot entirely rule out that any lessening of muscle mass with age may impact results. On the other hand, it may indicate the need for a more stringent definition of SPS, whereby only patients with a persistent ratio < 0.6 should be diagnosed. Such a diagnostic criteria is already employed for chronic kidney disease, requiring at least two consecutive measurements below cutoff, present for a given duration.19

This is the first study investigating the association between eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio and mortality in a population based setting, and we have been able to demonstrate the long-term implications for mortality risk. In the OPRA cohort, women with an eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio < 0.6 had a more than one and a half times higher risk of death at 10-years. This concurs with non-population based studies that found increased risk at cutoffs of both < 0.6 and < 0.7, although follow-up times in these studies varies from one to just over five and a half years.

Interestingly, ratios between 0.6 and 0.69 were not associated with higher mortality, somewhat surprising in the light of a large study in patients referred for GFR determination; increased risk was already apparent at ratios of 1.0 to 0.85, with higher risk the lower the ratio.9 It could be related to statistical power, however one explanation for these differences could be that the present study excluded women with sarcopenia. If sarcopenic women were included in analyses and categorized with a low eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio, this could ‘falsely’ strengthen association with mortality since sarcopenia lowers plasma creatinine (therefore the probability of a low ratio), while sarcopenia itself is associated with mortality.26 Another explanation for the difference in risk estimates could be the difference in patients (general health as well as age) referred for GFR determination compared to the population based OPRA cohort. Nevertheless, our results indicate that a ratio of < 0.6 may be most appropriate as a diagnostic threshold for SPS in elderly women. Our results also confirm suggestions that different clinical settings could require different cutoff levels.18

This is the first study investigating the association between eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio and mortality risk in a population based setting, and limitations are acknowledged. Firstly, the OPRA cohort was originally designed to study fractures and therefore kidney related outcomes such as measured GFR and urine albumin were not assessed. Other studies report an increased mortality risk with SPS, even with normal GFR. This study does not have data on measured GFR, hence, it is for future studies to investigate this research question in a population based setting. While, as with measured GFR, data on urine albumin would have provided a more comprehensive picture of the participants kidney function, it is not essential for investigating prevalence and associated adverse outcomes of SPS. Urine albumin is important in assessing an individual’s kidney disease, not just to estimate kidney damage, but also for grading according to the 2012 Kidney Disease Improving Global Outcome guidelines. However, eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio (SPS) is a newly described syndrome which does not take urine albumin into consideration. At the same time, the combination of SPS and urine albumin would probably provide a better prediction tool to identify individuals at risk of adverse outcomes. This will be addressed in future studies.

The longitudinal design of the OPRA cohort enables evaluation of kidney function over time and across multiple time points. Also, in contrast to other studies, OPRA includes information on sarcopenia and glucocorticoid treatment, two significant non-renal factors affecting creatinine and cystatin C and which allows us to establish an accurate picture of eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio in the general elderly population. In addition, the long follow-up time of ten years makes this population based study unique. However, the present study lacks information on cause of death which would have been advantageous, considering eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratios of < 0.6 and < 0.7 have been associated with a variety of cardiovascular outcomes. This association cannot be investigated in the present setting, although the association between the eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio and mortality was significant even after adjusting for a proxy for CVD (i.e. medications associated with cardiovascular diseases). Furthermore, the OPRA cohort does not have information on cognitive impairment, an important factor associated with both mortality and chronic kidney disease. However, given that all participants were community dwelling and participated in advance testing, the number of participants with severe cognitive impairment is probably low. While mortality and loss to follow-up due to reasons such as illness or moving to a senior home, lower the numbers at the follow-up visits, reduction in subject numbers is inevitable in this age group. Although, prevalence of SPS at follow up (age 80 and 85) should be interpreted with this in view, eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio of < 0.6 is relatively stable over follow up.

Though participants in the OPRA cohort were randomly selected and no exclusion criteria applied, participants may be healthier than those who declined (21). This is not an uncommon phenomenon in elderly populations (22), and it may indicate that the actual prevalence of eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratios < 0.6 and < 0.7 could be higher. Still, participation rate at age 75 was high (65%), increasing the likelihood we have a representative sample of average 75 year old women. Lastly, only Caucasian women of the same age were included in the OPRA cohort, which means that conclusions may not apply to men, other ages or other ethnicities. The authors look forward to future studies including both sexes in a diversified setting.

In conclusion, eGFR\textsubscript{cysC}/eGFR\textsubscript{crea} ratio < 0.6 was common, affecting almost one in ten women at age 75. Mortality risk was increased at this threshold indicating it might be an appropriate cutoff in elderly women. Our findings prompt the need for further research, especially in other community based cohorts and including men.

Material and methods

Subjects. The Osteoporosis Prospective Risk Assessment (OPRA) cohort is a population based study originally designed as a fracture study.23 From 1995 to 1999, 1604 75 year old women were randomly and without exclusion criteria selected from the city archives of Malmö and invited by letter to participate. Of these, 32 could not be reached despite several attempts, while 152 stated illness and 376 unwillingness as a cause for non-participation, leaving 1044 women attending the baseline investigation (65% response rate). The first follow-up investigation took place after five years (age 80, n = 715) and the second after ten years (age 85, n = 382).

The present study uses data from those women with available cystatin C and creatinine values, corresponding to 963, 683 and 355 at respective visits. Missing values reflect a random loss across the cohort (for example, lack
of serum, inability to provide a blood sample, hemolysis or failed analysis) and not a systematic error or selection. SPS should only be diagnosed in the absence of non-renal factors affecting cysC or creatinine. Hence, women with sarcopenia and/or taking glucocorticoids, or with missing values in any of these were excluded from the analyses, equating to 114 women at age 75 and 114 and 69 at age 80 and 85, respectively. This resulted in a final dataset of 849 women at baseline (age 75), with 569 and 286 at the five and ten year follow-ups, respectively. The study was approved by the regional ethical review board in Lund (Dnr: 2014804) and performed in accordance with the Helsinki declaration. All participants provided written informed consent.

**General chemistry.** Blood samples were collected non-fasting before noon and stored at −80°C. Analyses were performed at the Department of Clinical Chemistry, Skåne University Hospital, Sweden. Details on analyses of cystatin C and creatinine has been described elsewhere. In short, plasma cystatin C from all visits were analyzed in batch in 2015 using a Cobas auto-analyser adjusted to the international reference preparation ERM-DA 471/IFCC (Roche Diagnostics, Mannheim, Germany, CV ranging from 2.2 to 1.2%). Due to study duration analyzed in batch in 2015 using a Cobas auto-analyser adjusted to the international reference preparation ERM-DA 471/IFCC. (Roche Diagnostics, Mannheim, Germany, CV ranging from 2.2 to 1.2%). Due to study duration and methodological updates, plasma creatinine was analyzed with a Beckman synchron LX20-4 (Beckman-Coulter, CA, USA) or using the Cobas method. All creatinine samples have been adjusted to the Cobas method to ensure homogeneity and allow comparison between different time points and all values are IDMS traceable. Other biochemistry (plasma CRP, calcium, albumin, phosphate and serum PTH and 25OHD3) were analyzed in accordance with routine procedures at the time of study.

**Kidney function and eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio.** Estimated Glomerular Filtration Rate (eGFR, mL/min/1.73 m²) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study equation based on cystatin C (eGFR<sub>cysC</sub>) and creatinine (eGFR<sub>crea</sub>). chosen because of its wide international use. CKD-EPI study equation using creatinine:

\[
\begin{align*}
\text{p-Cr} \leq 62 \, \mu\text{mol/L:} & \quad 144 \times (\text{p-Cr}/(0.7 \times 88.4))^{-0.329} \\
\text{p-Cr} > 62 \, \mu\text{mol/L:} & \quad 144 \times (\text{p-Cr}/(0.7 \times 88.4))^{-1.209} \\
\end{align*}
\]

CKD-EPI study equation using cystatin C:

\[
\begin{align*}
\text{p-CyC} \leq 0.8 \, \text{mg/L:} & \quad 133 \times (\text{p-cysC}/0.8)^{-0.499} \\
\text{p-CyC} > 0.8 \, \text{mg/L:} & \quad 133 \times (\text{p-cysC}/0.8)^{-1.328} \\
\end{align*}
\]

For purpose of comparison to other studies, analyses based on eGFR calculated using the LM-rev and CAPA study equations were also performed (supplementary material). LM-rev and CAPA have been developed from individuals in the same geographical region. SPS is based on the ratio of eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> and while no disease definition yet exists, we used two cutoffs to estimate prevalence of the syndrome based on the available literature, eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio < 0.6 or < 0.7. Since available data suggest risk estimation may differ based on the gradient of the eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio, we also report prevalence and comorbidities for women with a ratio from 0.6 to 0.69.

**Sarcopenia.** Sarcopenia, characterized by low muscle quantity and quality, was defined in accordance with the updated 2018 guidelines from the European Working Group on Sarcopenia in Older People, as low muscle function plus low muscle mass. Muscle function was defined as low knee strength (<157 Nm, equating to HGS<16 kg). Muscle mass was measured using dual-energy x-ray absorptiometry. Low muscle mass was defined as <5.5 kg/m², through dividing appendicular skeletal lean mass (ASL), by height squared (ASL/height², kg/m²). In the present study we excluded women with sarcopenia due to the risk of low muscle mass rendering a low plasma creatinine, and thus high eGFR<sub>crea</sub>, which could give a false low eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio.

**Mortality.** Date of death was obtained through the Swedish national population register and followed for ten years.

**Other assessments.** At study start and each follow-up investigation, assessment included anthropometrics and a detailed questionnaire on medication, diseases and lifestyle. Information about previous CVD and high blood pressure (HBP) was not available at baseline and derived from medication information. HBP was defined as treatment with any anti-hypertensive and CVD as anti-hypertensive treatment in combination with an anticoagulant or lipid-modifying agent or treatment with only vasodilators (organic nitrates). Hence, CVD at baseline should be considered as an indirect measure of CVD. Information on CVD (i.e. myocardial infarction, angina pectoris or stroke) was available at the five and ten year follow-up. Data on physical activity were self-reported and categorized as: (1) bedbound or moving with help from other people, (2) using walking aid, inside and out and 3) walk and exercise unhindered.

**Statistics.** Descriptive data is reported as mean with standard deviation (SD) or median with interquartile range (IQR). Differences in distribution of co-morbidities based on eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio (three categories: >0.7, 0.6–0.69 or <0.6) were compared using Chi-squared. To explore eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio over time, we investigated how many of the women with a ratio <0.6 at age 75 maintained this ratio at age 80. We then repeated these calculations from age 80 to 85.
Ten year mortality risk was investigated for five categories of eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio: >0.9 (reference category), 0.8–0.89, 0.7–0.79, 0.6–0.69 and <0.6 using cox proportional hazard models, unadjusted and adjusted for diabetes, high blood pressure, cardiovascular disease and current smoking status (model 1) and additionally for physical activity (model 2). The proportional hazards assumption was tested through log minus log plots. In addition, risk calculation with eGFR<sub>cysC</sub>/eGFR<sub>crea</sub> ratio as a continuous variable were performed. Kaplan Meier curves were used to describe survival over ten years.

All statistical analyses were made using SPSS (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY). A p-value below 0.05 was considered nominally significant.

**Statement of ethics.** Participants in the OPRA study gave written informed consent and study protocol has been approved by the Regional Ethical Review Board in Lund. The study was conducted in accordance with the Helsinki declaration.

**Data availability**
Data available on request from the corresponding author Kristina Åkesson at e-mail: kristina.akesson@med.lu.se.

Received: 1 July 2021; Accepted: 15 November 2021
Published online: 24 January 2022

**References**

1. Grubb, A. et al. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: "Shrunken pore syndrome". *Scand. J. Clin. Lab. Invest.* 78(4), 333–340 (2015).
2. Grubb, A. Shrunken pore syndrome - a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. *Clin. Biochem.* 83, 12–20 (2020).
3. Grubb, A. Glomerular filtration and Shrunken pore syndrome in children and adults. *Acta Paediatr.* 110, 2503–2508 (2021).
4. Purde, M. T. et al. The cystatin C/creatinine ratio, a marker of glomerular filtration quality: associated factors, reference intervals, and prediction of morbidity and mortality in healthy seniors. *Transl. Res.* 169, 80–90 (2016).
5. Öberg, C. M., Lindström, M., Grubb, A. & Christensson, A. Potential relationship between eGFR<sub>cystatinC</sub>/eGFR<sub>creatinine</sub>-ratio and glomerular basement membrane thickness in diabetic kidney disease. *Physiol. Rep.* 9(13), e4939 (2021).
6. Åkesson, A. et al. Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. *Scand. J. Clin. Lab. Invest.* 80(5), 412–422 (2020).
7. Dardashti, A., Nozhoohoosh, S., Grubb, A. & Bjursten, H. Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. *Scand. J. Clin. Lab. Invest.* 76(1), 74–81 (2016).
8. Jonsson, M., Åkesson, A., Hommel, A., Grubb, A. & Bentzer, P. Markers of renal function at admission and mortality in hip fracture patients - a single center prospective observational study. *Scand. J. Clin. Lab. Invest.* 56, 1–7 (2021).
9. Herou, E. et al. The mortality increase in cardiac surgery patients associated with Shrunken pore syndrome correlates with the eGFR<sub>cystatinC</sub>/eGFR<sub>creatinine</sub> ratio. *Scand. J. Clin. Lab. Invest.* 79(3), 167–173 (2019).
10. Zhou, H., Yang, M., He, X. & Xu, N. eGFR, cystatin C and creatinine in Shrunken pore syndrome. *Clin. Chim. Acta.* 498, 1–5 (2019).
11. Xhakollari, L. et al. Proteins linked to atherosclerosis and cell proliferation are associated with the Shrunken pore syndrome in heart failure patients: Shrunken pore syndrome and proteomic associations. *Proteomics Clin. Appl.* 15, e2000089 (2021).
12. Ljungberg, J. et al. Mild impairment of renal function (Shrunken pore syndrome) is associated with increased risk for future surgery for aortic stenosis. *Scand. J. Clin. Lab. Invest.* 79(5), 524–530 (2019).
13. Christensson, A. et al. The Shrunken pore syndrome is associated with declined right ventricular systolic function in a heart failure population—the HARVEST study. *Scand. J. Clin. Lab. Invest.* 76(7), 568–574 (2016).
14. den Bakker, E. et al. Evidence for Shrunken pore syndrome in children. *Scand. J. Clin. Lab. Invest.* 80(1), 32–38 (2020).
15. Kristensen, K. et al. Temporal changes of the plasma levels of cystatin C, beta-trace protein, beta2-microglobulin, urate and creatinine during pregnancy indicate continuous alterations in the renal filtration process. *Scand. J. Clin. Lab. Invest.* 67(6), 612–618 (2007).
16. Matsushita, K. et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 375(9731), 2073–2081 (2010).
17. Yoshii, I. & Nishiyama, S. The impact of Shrunken pore syndrome in patient with rheumatic diseases on bone mineral metabolism. *Scand. J. Clin. Lab. Invest.* 81(1), 72–81 (2021).
18. Iyagi, I., Agrawal, U., Amitabh, V., Jain, A. K. & Saxena, S. Thickness of glomerular and tubular basement membranes in preclinical and clinical stages of diabetic nephropathy. *Indian J. Nephrol.* 18(2), 64–69 (2008).
19. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int. Suppl.* 2013(3), 1–150 (2012).
20. Cruz-Jentoft, A. J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* 48(1), 16–31 (2019).
21. Willhöft, A., Åkesson, K. & Gerdhem, P. External validity of a population-based study on osteoporosis and fracture. *Acta Orthop.* 85(4), 433–437 (2014).
22. Golomb, B. A. et al. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. *BMJ Open* 2(6), e000833 (2012).
23. Gerdhem, P. et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. *J. Bone Miner Res.* 19(3), 386–393 (2004).
24. Malcolm, L., Mcguigan, F. E., Christensson, A. & Åkesson, K. E. Longitudinal changes in kidney function estimated from cystatin C and its association with mortality in elderly women. *Nephron* 114(6), 290–298 (2020).
25. Malcolm, L. et al. Declining estimated glomerular filtration rate and its association with mortality and comorbidity over 10 years in elderly women. *Nephron* 130(4), 245–255 (2020).
26. Grubb, A. et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. *Clin. Chem.* 60(7), 974–986 (2014).
27. Berglundh, S., Malcolm, L., Luthman, H., Mcguigan, F. & Åkesson, K. C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. *Osteoporos Int.* 26(2), 727–735 (2015).
28. Malcolm, L., Mcguigan, F., Christensson, A. & Åkesson, K. E. Reduced kidney function is associated with BMD, bone loss and markers of mineral homeostasis in older women: a 10-year longitudinal study. *Osteoporos Int.* 28(12), 3463–3473 (2017).
29. Inker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N. Engl. J. Med.* 367(1), 20–29 (2012).
30. Björk, J., Grubb, A., Sterner, G. & Nyman, U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. *Scand. J. Clin. Lab. Invest.* 71(3), 232–239 (2011).
Acknowledgements
Thanks are extended to funders, the research nurses and data management at the Clinical and Molecular Osteoporosis Research Unit, Malmö; and to all the women who kindly participated in the study. Thanks are also extended to Paul Gerdhem and Karl Obrant, for initiating the cohort.

Author contributions
Conception or design, or analysis and interpretation of data, or both (L.M., F.M., A.C., K.Å.). Data analysis (L.M.). L.M. takes responsibility for the integrity of the data analysis. Drafting the manuscript (L.M., F.M., K.Å.) or revising it (L.M., F.M., A.C., K.Å.). Providing intellectual content of critical importance to the work (L.M., F.M., A.C., K.Å.). Final approval of the version to be published (L.M., F.M., A.C., K.Å.). Agree to be accountable for accuracy and integrity of the work (L.M., F.M., A.C., K.Å.).

Funding
Open access funding provided by Lund University. This work was supported by grants from the Swedish Research Council (K2015-52X-14691-13-4), Greta and Johan Kock Foundation, A. Pålsson Foundation, A. Osterlund Foundation, H Järnhardt Foundation, King Gustav V 80 year fund, Swedish Rheumatism foundation, the Swedish Kidney Foundation, Njurstiftelsen, ALF, Syssonen Lundgrens stiftelse, the Royal Physiographic Society of Lund, Skåne University Hospital Research Fund and the Research and Development Council of Region Skåne, Sweden.

Competing interests
The authors declare no competing interests. L. Malmgren has received lecture fees from Amgen. K. Åkesson has received lecture fees from Amgen, Eli Lilly, Renapharma, UCB Pharma. All other authors have nothing to disclose.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-05320-w.

Correspondence and requests for materials should be addressed to K.E.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022